2025
Quinagolide vaginal ring for reduction of endometriotic lesions: Results from the QLARITY trial
Pellicer A, Taylor H, Alberich-Bayarri A, Liu Y, Gamborg M, Barletta K, Pinton P, Heiser P, Bagger Y. Quinagolide vaginal ring for reduction of endometriotic lesions: Results from the QLARITY trial. European Journal Of Obstetrics & Gynecology And Reproductive Biology 2025, 310: 113946. PMID: 40188683, DOI: 10.1016/j.ejogrb.2025.113946.Peer-Reviewed Original ResearchConceptsDeep infiltrating endometriosisVaginal ringNo significant differenceLesion sizeBleeding patternsMenstrual cycleSignificant differenceImaging biomarkersSerum prolactin levelsPhase 2 trialMenstrual bleeding patternsEndpoint of reductionPatient-reported outcomesHigh-resolution MRIInfiltrating endometriosisPlacebo groupDouble-blindPlacebo-ControlledAdvanced diseaseEndometriotic lesionsPrimary endpointPain reductionSecondary endpointsProlactin levelsAdverse events
2021
Willingness of Women with Endometriosis Planning to Undergo IVF to Participate in a Randomized Clinical Trial and the Effects of the COVID-19 Pandemic on Potential Participation
Pretzel S, Kuhn K, Pal L, Polotsky A, Taylor HS, Zhang H, Robins J, Young SL, Santoro N. Willingness of Women with Endometriosis Planning to Undergo IVF to Participate in a Randomized Clinical Trial and the Effects of the COVID-19 Pandemic on Potential Participation. Reproductive Sciences 2021, 29: 620-626. PMID: 34363198, PMCID: PMC8345905, DOI: 10.1007/s43032-021-00705-0.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultChoice BehaviorCOVID-19Double-Blind MethodElectronic Health RecordsEndometriosisFemaleFertility Agents, FemaleFertilization in VitroGonadotropin-Releasing HormoneHealth Knowledge, Attitudes, PracticeHormone AntagonistsHumansInfertility, FemaleLive BirthPatient SelectionPregnancyPregnancy RateResearch SubjectsTreatment OutcomeUnited StatesYoung AdultConceptsGnRH antagonistClinical trialsEndometriosis diagnosisSuperior live birth ratesCOVID-19Relevant ICD-10 codesOral GnRH antagonistLive birth rateAge-eligible womenICD-10 codesElectronic medical recordsSurvey of womenIVF cyclesEligible womenWillingness of womenInfertility diagnosisMedical recordsFertility treatmentIVFWomenDiagnosisTrialsBirth rateTreatmentCOVID-19 pandemic
2020
Responsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis
Pokrzywinski RM, Soliman AM, Snabes MC, Chen J, Taylor HS, Coyne KS. Responsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis. Fertility And Sterility 2020, 115: 423-430. PMID: 33066973, DOI: 10.1016/j.fertnstert.2020.07.013.Peer-Reviewed Original ResearchConceptsSevere endometriosis-associated painEndometriosis-associated painNumerical rating scaleNonmenstrual pelvic painPelvic painWorst painMonth 3Rating ScalePain numerical rating scaleMeaningful changePremenopausal womenSevere endometriosisGlobal ImpressionClinical trialsMAIN OUTCOMEPainDysmenorrheaPhase IIIWomenElagolixResponsivenessTrialsPlaceboEndometriosisPatientsLessons from KEEPS: the Kronos Early Estrogen Prevention Study
Miller VM, Taylor HS, Naftolin F, Manson JE, Gleason CE, Brinton EA, Kling JM, Cedars MI, Dowling NM, Kantarci K, Harman SM. Lessons from KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric 2020, 24: 139-145. PMID: 32880220, PMCID: PMC8108428, DOI: 10.1080/13697137.2020.1804545.Peer-Reviewed Original ResearchConceptsKronos Early Estrogen Prevention StudyCarotid intima-medial thicknessPrevention StudyCardiovascular diseaseOral conjugated equine estrogenClinical CVD eventsUse of MHTOvert cardiovascular diseasePlacebo-controlled trialConjugated equine estrogensCoronary artery calciumIntima-medial thicknessMode of deliveryUptake of estrogensMood/anxietyAge-related increaseGenetic variantsCVD eventsAgatston unitsArtery calciumSymptom reliefPlacebo pillsEquine estrogensMenopausal womenMenopausal symptomsTreatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial
Donnez J, Taylor HS, Taylor RN, Akin MD, Tatarchuk TF, Wilk K, Gotteland JP, Lecomte V, Bestel E. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial. Fertility And Sterility 2020, 114: 44-55. PMID: 32505383, DOI: 10.1016/j.fertnstert.2020.02.114.Peer-Reviewed Original ResearchConceptsEndometriosis-associated painBone mineral densityNon-menstrual pelvic painPelvic painDose-dependent fashionSerum estradiolOral gonadotropin-releasing hormone antagonistSevere endometriosis-associated painGonadotropin-releasing hormone antagonistOverall pelvic painRates of amenorrheaDose-ranging trialRandomized clinical trialsNumber of respondersPrimary endpointBMD lossTotal hipFemoral neckHormone antagonistClinical centersParallel groupClinical trialsMineral densityLife measuresMAIN OUTCOME
2019
Responsiveness Evaluation and Recommendation for Responder Thresholds for Endometriosis Health Profile-30: Analysis of Two Phase III Clinical Trials
Pokrzywinski R, Soliman A, Chen J, Snabes M, Taylor H, Coyne K. Responsiveness Evaluation and Recommendation for Responder Thresholds for Endometriosis Health Profile-30: Analysis of Two Phase III Clinical Trials. Journal Of Women's Health 2019, 29: 253-261. PMID: 31855102, DOI: 10.1089/jwh.2019.7788.Peer-Reviewed Original ResearchConceptsEndometriosis Health Profile-30Nonmenstrual pelvic painClinical trialsResponder thresholdSevere endometriosis-associated painPhase III clinical trialsEndometriosis-associated painEndometriosis-related painPatient Global ImpressionGoal of treatmentPatient-reported impactPelvic painMonth 3Month 6EHP-30Global ImpressionTreatment efficacyDay 1Large effect sizesHealth statusPainResponsiveness evaluationDaily diariesPhase IIIDistribution-based analysisImpact of menopausal hormone formulations on pituitary-ovarian regulatory feedback
Kling JM, Dowling NM, Bimonte-Nelson HA, Gleason CE, Kantarci K, Manson JE, Taylor HS, Brinton EA, Lobo RA, Cedars MI, Pal L, Neal-Perry G, Naftolin F, Harman SM, Miller VM. Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback. AJP Regulatory Integrative And Comparative Physiology 2019, 317: r912-r920. PMID: 31663769, PMCID: PMC6957372, DOI: 10.1152/ajpregu.00234.2019.Peer-Reviewed Original ResearchConceptsFollicle-stimulating hormoneKronos Early Estrogen Prevention StudyHormone levelsHormone therapyT-E2Menopausal womenTreatment groupsOral conjugated equine estrogenCommon hormone therapiesPituitary-ovarian hormonesPostmenopausal hormone therapyActive treatment groupConjugated equine estrogensMo of treatmentDouble-blinded treatmentPlacebo groupEquine estrogensMenopausal transitionPrevention StudyO-CEEHormonal modulationBaseline levelsCognitive declinePlaceboHormone formulations
2018
Long-Term Outcomes of Elagolix in Women With Endometriosis
Surrey E, Taylor HS, Giudice L, Lessey BA, Abrao MS, Archer DF, Diamond MP, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Singh SS, Rechberger T, Agarwal SK, Duan WR, Schwefel B, Thomas JW, Peloso PM, Ng J, Soliman AM, Chwalisz K. Long-Term Outcomes of Elagolix in Women With Endometriosis. Obstetrics And Gynecology 2018, 132: 147-160. PMID: 29889764, DOI: 10.1097/aog.0000000000002675.Peer-Reviewed Original ResearchConceptsMonths of treatmentResponder rateAdverse eventsPlacebo-controlled phase 3 trialGonadotropin-releasing hormone antagonistBone mineral density assessmentCoprimary efficacy endpointsEndometriosis-associated painNonmenstrual pelvic painPelvic pain scoresSafety of elagolixCommon adverse eventsPhase 3 trialProportion of respondersNew safety concernsBone mineral densityClinical laboratory testsElagolix dosesElagolix treatmentEndometrial findingsEfficacy endpointPain scoresPelvic painHot flushesTerm outcomesEffects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS)
Cintron D, Lahr BD, Bailey KR, Santoro N, Lloyd R, Manson JE, Neal-Perry G, Pal L, Taylor HS, Wharton W, Naftolin F, Harman SM, Miller VM. Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Menopause The Journal Of The North American Menopause Society 2018, 25: 145-153. PMID: 28832429, PMCID: PMC5771895, DOI: 10.1097/gme.0000000000000971.Peer-Reviewed Original ResearchConceptsKronos Early Estrogen Prevention StudyHormone therapyDomains of sleepSleep qualityDomain scoresMenopausal womenPrevention StudySleep domainsGlobal Pittsburgh Sleep Quality Index scoreOral conjugated equine estrogenPittsburgh Sleep Quality Index scorePittsburgh Sleep Quality IndexVasomotor symptom scoresConjugated equine estrogensSleep Quality IndexPoor sleep qualityGlobal sleep qualitySeverity of symptomsGlobal sleep scoreQuality Index scoresMenopausal hormonesVMS severityPostmenopausal womenVasomotor symptomsSpearman correlation coefficient
2017
Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS)
Taylor HS, Tal A, Pal L, Li F, Black DM, Brinton EA, Budoff MJ, Cedars MI, Du W, Hodis HN, Lobo RA, Manson JE, Merriam GR, Miller VM, Naftolin F, Neal-Perry G, Santoro NF, Harman SM. Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS). JAMA Internal Medicine 2017, 177: 1471-1479. PMID: 28846767, PMCID: PMC5710212, DOI: 10.1001/jamainternmed.2017.3877.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAdultDouble-Blind MethodEstradiolEstrogen Replacement TherapyEstrogensEstrogens, Conjugated (USP)FemaleFollow-Up StudiesGlucuronatesHumansMiddle AgedPostmenopauseProgesteroneProgestinsProspective StudiesPsychiatric Status Rating ScalesQuality of LifeRisk FactorsSexual Dysfunction, PhysiologicalTime FactorsWomen's HealthConceptsKronos Early Estrogen Prevention StudyLow sexual functionTransdermal estrogen therapySexual functionAncillary studiesEstrogen therapyPostmenopausal womenPrevention StudyT-E2Female Sexual Function InventoryOral conjugated equine estrogenOverall scoreLower FSFI scoresEarly postmenopausal womenMenopausal hormone therapyPlacebo-controlled trialOral micronized progesteroneConjugated equine estrogensSexual Function InventoryLast menstrual periodEffects of OralQuality of lifeProportion of womenSymptoms of distressMicronized progesteroneTreatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, Diamond MP, Surrey E, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Rowan JP, Duan WR, Ng J, Schwefel B, Thomas JW, Jain RI, Chwalisz K. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. New England Journal Of Medicine 2017, 377: 28-40. PMID: 28525302, DOI: 10.1056/nejmoa1700089.Peer-Reviewed Original ResearchConceptsNonmenstrual pelvic painEndometriosis-associated painPelvic painClinical responsePercentage of womenPlacebo groupEnd pointPrimary efficacy end pointSevere endometriosis-associated painGonadotropin-releasing hormone antagonistOral GnRH antagonistRescue analgesic agentsEfficacy end pointPrimary end pointPhase 3 trialClinical response criteriaEstrogen-dependent conditionDaily electronic diaryBone mineral densityProportion of womenCorresponding percentagesEndometrial findingsEstrogen suppressionPain scoresHot flushes
2016
Effects of hormones on skin wrinkles and rigidity vary by race/ethnicity: four-year follow-up from the ancillary skin study of the Kronos Early Estrogen Prevention Study
Owen CM, Pal L, Mumford SL, Freeman R, Isaac B, McDonald L, Santoro N, Taylor HS, Wolff EF. Effects of hormones on skin wrinkles and rigidity vary by race/ethnicity: four-year follow-up from the ancillary skin study of the Kronos Early Estrogen Prevention Study. Fertility And Sterility 2016, 106: 1170-1175.e3. PMID: 27393520, DOI: 10.1016/j.fertnstert.2016.06.023.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAdultBlack or African AmericanDouble-Blind MethodDrug CombinationsElasticityEstradiolEstrogen Replacement TherapyEstrogens, Conjugated (USP)FemaleHumansMenopauseMiddle AgedProgesteroneSkinSkin AgingTime FactorsTransdermal PatchTreatment OutcomeUnited StatesWhite PeopleConceptsKronos Early Estrogen Prevention StudyConjugated equine estrogensHormone therapyRace/ethnicityRigidity scoresSkin wrinklesPrevention StudyOral conjugated equine estrogenWhite womenLowest wrinkle scoresPlacebo-controlled trialLast menstrual periodAcademic medical centerBlack womenWrinkle scoreEffects of hormonesEquine estrogensMenopausal womenMenstrual periodMedical CenterMAIN OUTCOMESkin rigidityWomenPlaceboScores
2015
Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS–Cognitive and Affective Study
Gleason CE, Dowling NM, Wharton W, Manson JE, Miller VM, Atwood CS, Brinton EA, Cedars MI, Lobo RA, Merriam GR, Neal-Perry G, Santoro NF, Taylor HS, Black DM, Budoff MJ, Hodis HN, Naftolin F, Harman SM, Asthana S. Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS–Cognitive and Affective Study. PLOS Medicine 2015, 12: e1001833. PMID: 26035291, PMCID: PMC4452757, DOI: 10.1371/journal.pmed.1001833.Peer-Reviewed Original ResearchConceptsCognitive outcomesMood outcomesVerbal learning/memoryAttention/executive functionEffect sizeAuditory attention/Kronos Early Estrogen Prevention StudyAffective studiesLearning/memoryModified Mini-Mental State ExaminationMenopausal hormone therapyMedium effect sizeMini-Mental State ExaminationTreatment-related benefitsAttention/Cognitive factorsMental flexibilityExecutive functionMood measuresMood effectsAnxiety symptomsAge 65 y.Beneficial mood effectsCognitive AssessmentMood states
2014
Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial.
Harman SM, Black DM, Naftolin F, Brinton EA, Budoff MJ, Cedars MI, Hopkins PN, Lobo RA, Manson JE, Merriam GR, Miller VM, Neal-Perry G, Santoro N, Taylor HS, Vittinghoff E, Yan M, Hodis HN. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Annals Of Internal Medicine 2014, 161: 249-60. PMID: 25069991, DOI: 10.7326/m14-0353.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAdultC-Reactive ProteinCarotid Intima-Media ThicknessCoronary Artery DiseaseDisease ProgressionDouble-Blind MethodEstradiolEstrogen Replacement TherapyEstrogensEstrogens, Conjugated (USP)FemaleHumansInsulin ResistanceLipidsMiddle AgedPostmenopauseProgesteroneRadiographyRisk FactorsSex Hormone-Binding GlobulinConceptsCarotid artery intima-media thicknessMenopausal hormone therapyCoronary artery calciumCVD riskMenopausal womenRisk factorsCardiovascular diseaseT-E2O-CEEHigh-density lipoprotein cholesterol levelsOral conjugated equine estrogenArtery intima-media thicknessEnd pointSex hormone-binding globulinCardiovascular risk factorsCVD risk factorsLipid-Lowering TherapyPrimary end pointSecondary end pointsSerious adverse eventsConjugated equine estrogensLipoprotein cholesterol levelsC-reactive proteinIntima-media thicknessHealthy menopausal womenThe KEEPS-Cognitive and Affective Study: Baseline Associations between Vascular Risk Factors and Cognition
Wharton W, Gleason CE, Dowling NM, Carlsson CM, Brinton EA, Santoro MN, Neal-Perry G, Taylor H, Naftolin F, Lobo RA, Merriam G, Manson JE, Cedars MI, Miller VM, Black DM, Budoff M, Hodis HN, Harman SM, Asthana S. The KEEPS-Cognitive and Affective Study: Baseline Associations between Vascular Risk Factors and Cognition. Journal Of Alzheimer’s Disease 2014, 40: 331-341. PMID: 24430001, PMCID: PMC4367860, DOI: 10.3233/jad-130245.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAdultAttentionBlood GlucoseBlood PressureCholesterol, HDLCholesterol, LDLCognition DisordersDouble-Blind MethodEstradiolEstrogensFemaleHormonesHumansLongitudinal StudiesMiddle AgedMood DisordersNeuropsychological TestsPsychiatric Status Rating ScalesRisk FactorsConceptsVascular risk factorsSystolic blood pressureBlood pressureRisk factorsAlzheimer's diseaseCognitive dysfunctionMidlife vascular risk factorsOral conjugated equine estrogenHigher systolic blood pressureConjugated equine estrogensLower blood pressureSerum estradiol levelsHigh blood pressurePostmenopausal womenVascular riskBP levelsEquine estrogensEstradiol levelsMenopausal womenParallel groupClinical trialsHormone levelsCognitive domainsBaseline associationsCognitive decline
2013
Ectopic fat and adipokines in metabolically benign overweight/obese women: The kronos early estrogen prevention study
Ogorodnikova AD, Khan UI, McGinn AP, Zeb I, Budoff MJ, Harman SM, Miller VM, Brinton EA, Manson JE, Hodis HN, Merriam GR, Cedars MI, Taylor HS, Naftolin F, Lobo RA, Santoro N, Wildman RP. Ectopic fat and adipokines in metabolically benign overweight/obese women: The kronos early estrogen prevention study. Obesity 2013, 21: 1726-1733. PMID: 23670850, PMCID: PMC3748250, DOI: 10.1002/oby.20200.Peer-Reviewed Original ResearchConceptsEctopic fatHepatic fatTop tertilePrevention StudyBottom tertileEpicardial fatKronos Early Estrogen Prevention StudyOverweight/obese womenOverweight/obese individualsCardiometabolic risk profileNormal-weight womenHMW adiponectin levelsOverweight/obeseNormal-weight individualsCross-sectional analysisObese womenWeight womenAdiponectin levelsMetabolic syndromeHMW adiponectinObese individualsWeight individualsPericardial fatCardiovascular diseaseHigher odds
2012
Associations between retinol-binding protein 4 and cardiometabolic risk factors and subclinical atherosclerosis in recently postmenopausal women: cross-sectional analyses from the KEEPS study
Huang G, Wang D, Khan UI, Zeb I, Manson JE, Miller V, Hodis HN, Budoff MJ, Merriam GR, Harman MS, Brinton EA, Cedars MI, Su Y, Lobo RA, Naftolin F, Santoro N, Taylor HS, Wildman RP. Associations between retinol-binding protein 4 and cardiometabolic risk factors and subclinical atherosclerosis in recently postmenopausal women: cross-sectional analyses from the KEEPS study. Cardiovascular Diabetology 2012, 11: 52. PMID: 22587616, PMCID: PMC3461442, DOI: 10.1186/1475-2840-11-52.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAtherosclerosisBiomarkersBlood GlucoseBlood PressureC-Reactive ProteinCarotid Intima-Media ThicknessCoronary DiseaseCross-Sectional StudiesDouble-Blind MethodFemaleHormone Replacement TherapyHumansInsulinLife StyleLipidsMiddle AgedObesityPostmenopauseRadiographyRetinol-Binding Proteins, PlasmaRisk FactorsConceptsRetinol-binding protein 4Carotid artery intima-media thicknessCoronary artery calcificationCardiometabolic risk factorsRBP4 levelsHigher RBP4 levelsRisk factorsPostmenopausal womenCross-sectional analysisSubclinical atherosclerosisKronos Early Estrogen Prevention StudyArtery intima-media thicknessSubclinical coronary atherosclerosisResultsThe mean ageSerum RBP4 levelsProtein 4C-reactive proteinIntima-media thicknessAdditional risk factorsWestern blot analysisArtery calcificationCIMT levelsCoronary atherosclerosisBlood pressureHigh triglyceridesThe Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: Rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome
Legro RS, Kunselman AR, Brzyski RG, Casson PR, Diamond MP, Schlaff WD, Christman GM, Coutifaris C, Taylor HS, Eisenberg E, Santoro N, Zhang H, Network F. The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: Rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome. Contemporary Clinical Trials 2012, 33: 470-481. PMID: 22265923, PMCID: PMC3312939, DOI: 10.1016/j.cct.2011.12.005.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic AgentsChi-Square DistributionClomipheneDouble-Blind MethodFemaleFertility Agents, FemaleHealth Status IndicatorsHirsutismHumansHyperandrogenismInfertility, FemaleLetrozoleMiddle AgedNitrilesOvulation InductionPolycystic Ovary SyndromePregnancyQuality of LifeResearch DesignTriazolesWomen's HealthYoung AdultConceptsPolycystic ovary syndromeClomiphene citrateOvary syndromeInfertile womenTreatment armsDouble-blind clinical trialSelective estrogen receptor modulatorsMajor infertility factorOral clomiphene citrateMultiple pregnancy rateFirst-line treatmentLive birth rateEstrogen receptor modulatorsDifferent treatment armsTreatment of infertilityPoor ovulatory responseEndometrial effectsII trialII studyLine treatmentInfertility factorsProgestin withdrawalAromatase inhibitorsClinical trialsFemale infertility
2011
Intra-thoracic fat, cardiometabolic risk factors, and subclinical cardiovascular disease in healthy, recently menopausal women screened for the Kronos Early Estrogen Prevention Study (KEEPS)
Huang G, Wang D, Zeb I, Budoff MJ, Harman SM, Miller V, Brinton EA, Khoudary S, Manson JE, Sowers MR, Hodis HN, Merriam GR, Cedars MI, Taylor HS, Naftolin F, Lobo RA, Santoro N, Wildman RP. Intra-thoracic fat, cardiometabolic risk factors, and subclinical cardiovascular disease in healthy, recently menopausal women screened for the Kronos Early Estrogen Prevention Study (KEEPS). Atherosclerosis 2011, 221: 198-205. PMID: 22209479, PMCID: PMC3288598, DOI: 10.1016/j.atherosclerosis.2011.12.004.Peer-Reviewed Original ResearchMeSH KeywordsAdiposityAdultAge FactorsAsymptomatic DiseasesBiomarkersBody Mass IndexC-Reactive ProteinCoronary Artery DiseaseDouble-Blind MethodEstrogen Replacement TherapyFemaleHumansInsulinLinear ModelsLiverLogistic ModelsMetabolic SyndromeMiddle AgedMultivariate AnalysisOdds RatioPericardiumPostmenopauseProspective StudiesRisk AssessmentRisk FactorsTomography, X-Ray ComputedUnited StatesVascular CalcificationWaist CircumferenceConceptsKronos Early Estrogen Prevention StudyCoronary artery calcificationIntra-hepatic fatCVD risk markersThoracic fatHs-CRPPrevention StudyRisk markersRisk factorsCardiac fatCardiovascular disease risk factorsCardiometabolic risk factorsDisease risk factorsSubclinical cardiovascular diseaseSubclinical atherosclerosis burdenThoracic adipose tissueAtherosclerosis burdenMultivariable adjustmentArtery calcificationCVD riskPostmenopausal womenSubclinical atherosclerosisMenopausal womenHepatic fatAdiposity measures
2010
Skin wrinkles and rigidity in early postmenopausal women vary by race/ethnicity: baseline characteristics of the skin ancillary study of the KEEPS trial
Wolff E, Pal L, Altun T, Madankumar R, Freeman R, Amin H, Harman M, Santoro N, Taylor HS. Skin wrinkles and rigidity in early postmenopausal women vary by race/ethnicity: baseline characteristics of the skin ancillary study of the KEEPS trial. Fertility And Sterility 2010, 95: 658-662.e3. PMID: 20971461, PMCID: PMC3026089, DOI: 10.1016/j.fertnstert.2010.09.025.Peer-Reviewed Original ResearchConceptsKronos Early Estrogen Prevention StudyEarly menopausal womenBody mass indexMenopausal womenHormone therapySkin wrinklesEffects of HTLowest wrinkle scoresEarly postmenopausal womenSkin wrinklingUniversity Medical CenterSignificant racial differencesSkin characteristicsRace/ethnic groupsSkin rigidityRace/ethnicityMenopausal participantsBaseline characteristicsPostmenopausal womenMulticenter trialMass indexPrevention StudyAncillary studiesMedical CenterStudy group
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply